What are the adverse effects of Gadolinium (Gadolinium-based contrast agent), including brain deposition?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Article Review Status
Submitted
Under Review
Approved

Last updated: April 24, 2025 • View editorial policy

From the Guidelines

Gadolinium-based contrast agents (GBCAs) should be used with caution, especially in patients with impaired kidney function, due to the risk of brain deposition and other adverse effects, and healthcare providers should prioritize the use of macrocyclic agents over linear agents when possible. The use of GBCAs can cause several adverse effects, including headache, nausea, dizziness, and injection site reactions, as well as more serious but rare reactions such as allergic responses and nephrogenic systemic fibrosis (NSF) in patients with impaired kidney function 1. Recent research has confirmed that gadolinium can deposit in brain tissues, particularly in the dentate nucleus and globus pallidus, even in patients with normal kidney function, with linear GBCAs (such as gadodiamide and gadopentetate dimeglumine) being more likely to cause deposition than macrocyclic agents (like gadoterate meglumine and gadobutrol) 2, 3, 4, 5.

Key Considerations

  • The risk of NSF is extremely low with the use of group II GBCAs, but the risk of brain deposition is still a concern 1.
  • Healthcare providers should carefully weigh the risks and benefits of using GBCAs, especially in patients requiring multiple contrast-enhanced MRIs over their lifetime 2, 3, 4, 5.
  • The use of macrocyclic agents is preferred over linear agents due to their lower risk of brain deposition and other adverse effects 2, 3, 4, 5.
  • Estimation of eGFR may not be required if macrocyclic contrast compounds are used, but caution is still necessary in patients with impaired kidney function 6.

Recommendations

  • Use GBCAs only when necessary and select more stable macrocyclic agents when possible.
  • Carefully weigh risks versus benefits, especially for patients requiring multiple contrast-enhanced MRIs over their lifetime.
  • Consider the potential harm of delayed diagnosis or misdiagnosis when deciding whether to use GBCAs in patients with impaired kidney function.

From the FDA Drug Label

Gadolinium is retained for months or years in brain, bone, and other organs. The most frequent (≥ 0.2%) adverse reactions in clinical studies were nausea, headache, injection site pain, injection site coldness, and rash.

The adverse effects of gadolinium include brain deposition, as it is retained for months or years in the brain. Other adverse reactions that have been reported include:

  • Nausea
  • Headache
  • Injection site pain
  • Injection site coldness
  • Rash 7

From the Research

Adverse Effects of Gadolinium

  • Gadolinium-based contrast agents have been associated with nephrogenic systemic fibrosis in patients with advanced kidney disease 8.
  • Trace amounts of gadolinium deposition in the brain and other organs have been reported after contrast exposure, even in patients with normal renal function 8, 9, 10.
  • Emerging evidence has linked MRI signal changes in deep nuclei of the brain with repeated administration of gadolinium-based contrast agents 9.
  • Gadolinium deposits have been confirmed in brain tissue, most notably in the dentate nuclei and globus pallidus 9, 10.

Brain Deposition

  • The extent of gadolinium deposition varies between agents, with linear contrast agents appearing to cause greater MRI signal changes than macrocyclic agents 9, 10.
  • Gadolinium deposition has been linked primarily with the use of linear, rather than macrocyclic, gadolinium-based contrast agents 10, 11.
  • Studies have shown that gadolinium may cause deposits in the brain independently of impaired renal function and in the presence of an intact blood-brain barrier 10.
  • One-year retention of gadolinium in the brain has been observed in a rodent model, with a large portion of gadolinium retained in the brain after repeated administration of gadodiamide 12.

Clinical Significance

  • The clinical significance of retained gadolinium in the brain, if any, remains unknown 9.
  • No data are available in human beings or animals to show adverse clinical effects due to the gadolinium deposition in the brain 9.
  • Further research is needed to explore the potential factors linked to gadolinium deposition and its clinical significance 10, 11.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.